SULLIVAN CHRISTOPHER RYAN (Interim CFO) sold 23.7% of their position (12.39K shares) of AVALO THERAPEUTICS, INC. on the open market
Open‑market sale worth $202.4K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 9/18/2026ACC: 0001810417-26-000023
Officer· Interim CFO
Since Apr 2020
-12.39K
Net shares
Net seller
$202.4K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
12.39K acquired · 24.79K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+12.39K
Price / share
$9.88
Trade value
$122.45K
% of position
31.1%
9/16/2026
39.90K→52.29K
Common Stock
Direct
Shares
−12.39K
Price / share
$16.33
Trade value
$202.44K
% of position
23.7%
9/16/2026
52.29K→39.90K
Total
Net shares
+0.00
Net value
-$79.98K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/16/2026 | M · Option Exercise | +12.39K | $9.88 | $122.45K | 31.1% | 39.90K | 52.29K |
| Common Stock Direct | 9/16/2026 | S · Sale | −12.39K | $16.33 | $202.44K | 23.7% | 52.29K | 39.90K |
| Total | +0.00 | -$79.98K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
12.39K shares
Shares
−12.39K
Strike price
9.88
Held after
83.85K
Exercisable
—
9/16/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock12.39K shares | 9/16/2026 | M · Option Exercise | −12.39K | 9.88 | — | 83.85K |